EPCAM Antibody

Datasheet
Code CSB-PA10799A0Rb
Size US$299
Image
  • Western Blot
    Positive WB detected in: Rat liver tissue
    All lanes: EPCAM antibody at 9.6μg/ml
    Secondary
    Goat polyclonal to rabbit IgG at 1/50000 dilution
    Predicted band size: 35 kDa
    Observed band size: 35 kDa

  • IHC image of CSB-PA10799A0Rb diluted at 1:400 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • IHC image of CSB-PA10799A0Rb diluted at 1:400 and staining in paraffin-embedded human appendix tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescence staining of MCF-7 cells with CSB-PA10799A0Rb at 1:133, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) EPCAM Polyclonal antibody
Uniprot No. P16422
Target Names EPCAM
Alternative Names 17 1A antibody; 323/A3 antibody; Adenocarcinoma associated antigen antibody; Adenocarcinoma-associated antigen antibody; Antigen identified by monoclonal antibody AUA1 antibody; AUA1 antibody; CD326 antibody; CD326 antigen antibody; Cell surface glycoprotein Trop 1 antibody; Cell surface glycoprotein Trop 2 antibody; Cell surface glycoprotein Trop-1 antibody; CO 17A antibody; CO17 1A antibody; CO17A antibody; DIAR5 antibody; EGP 2 antibody; EGP antibody; EGP2 antibody; EGP314 antibody; EGP40 antibody; Ep CAM antibody; Ep-CAM antibody; EPCAM antibody; EPCAM_HUMAN antibody; EpCAM1 antibody; Epithelial cell adhesion molecule antibody; Epithelial Cell Adhesion Molecule Intracellular Domain (EpCAM-ICD) antibody; Epithelial cell surface antigen antibody; Epithelial cellular adhesion molecule antibody; Epithelial glycoprotein 1 antibody; Epithelial glycoprotein 314 antibody; Epithelial glycoprotein antibody; ESA antibody; GA733 1 antibody; GA733 2 antibody; GA733-2 antibody; gastrointestinal tumor-associated antigen 2; 35-KD glycoprotein antibody; gp4 antibody; hEGP 2 antibody; hEGP314 antibody; HNPCC8 antibody; Human epithelial glycoprotein 2 antibody; KS 1/4 antigen antibody; KS1/4 antibody; KSA antibody; Ly74 antibody; Lymphocyte antigen 74 antibody; M1S 1 antibody; M1S2 antibody; M4S1 antibody; Major gastrointestinal tumor associated protein GA733 2 antibody; Major gastrointestinal tumor-associated protein GA733-2 antibody; mEGP314 antibody; Membrane component chromosome 4 surface marker (35kD glycoprotein) antibody; Membrane component; chromosome 4; surface marker 1 antibody; Membrane component; chromosome 4; surface marker antibody; MIC18 antibody; MK 1 antibody; Protein 289A antibody; TACD1 antibody; TACSTD1 antibody; TROP1 antibody; Tumor associated calcium signal transducer 1 antibody; Tumor associated calcium signal transducer 2 precursor antibody; Tumor-associated calcium signal transducer 1 antibody
Raised in Rabbit
Species Reactivity Human, Rat
Immunogen Recombinant Human Epithelial cell adhesion molecule protein (24-265AA)
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form Liquid
Tested Applications ELISA, WB, IHC, IF
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
IHC 1:200-1:500
IF 1:50-1:200
Protocols ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Gene References into Functions
  1. This study demonstrated a new approach using a combination of EpCAM and FRalpha as CTC-capture targets to increase the sensitivity of CTC detection in NSCLC efficiently, specifically, and quickly. PMID: 29352248
  2. Functions of EpCAM in physiological processes and diseases (Review). PMID: 30015855
  3. Our results suggest that GA733-2-Fc conjugated to ER-retention motif KDEL is a more efficient antigen to prevent tumor growth induced by colorectal carcinoma and minimize an allergic response. PMID: 30249898
  4. extracellular vesicles tend to localize in the intestinal tract associated with epithelial cell adhesion molecule PMID: 27721471
  5. Overexpression of EpCAM and melan-A is associated with malignant melanoma. PMID: 29076925
  6. Quercetin suppressed breast cancer stem cell proliferation, self-renewal, and invasiveness. It also lowered the expression levels of proteins related to tumorigenesis and cancer progression, such as aldehyde dehydrogenase 1A1, C-X-C chemokine receptor type 4, mucin 1, and epithelial cell adhesion molecules. PMID: 29353288
  7. Adenocarcinomas showed significantly higher staining scores of both VEGF and alphaSMA than squamous cell carcinomas did. In 42 cases of high CD31 score, five-year survival rate (87%) of patients with lung cancer showing mature tumor vessels was significantly better than that (69%) of patients with immature tumor vessels PMID: 29970536
  8. New EPCAM founder deletion causing Lynch Syndrome has been described in Polish population. PMID: 28369810
  9. The novel and updated insights in the EpCAM field by simplifying the understanding of the biological role of this fascinating molecule, and by showing the promising therapeutic tools that have been developed by various approaches which use antibodies and vaccines for different cancer types for the clear purpose of improving patient outcome. [review] PMID: 29759567
  10. This is the first demonstration that the low sensitivity of CellSearch(R) to detect circulating tumor cells in colorectal cancer patients is not due to the lack of EpCAM PMID: 28604994
  11. Findings indicate that epithelial cell adhesion molecule (EpCAM) can be used as an additional distinction-marker for cystic lesions of the sellar region. PMID: 27431859
  12. Data indicate that epithelial cell adhesion molecule (EpCAM) show high tumor distinctiveness. PMID: 28820475
  13. Low expressions of Oct4-EpCAM in IHC and CD133 in qPCR may reveal roles in gastric cancer PMID: 27557490
  14. EpCAM expression contributes to tumor resistance to chemotherapy in patients with ovarian cancer. PMID: 28574829
  15. The present findings suggest that Ep-CAM expression may be associated with CRC carcinogenesis, while the loss of Ep-CAM expression is correlated with the progression, metastasis, and poor prognosis of CRC. Ep-CAM expression may be a useful biomarker for the clinical diagnosis of CRC. PMID: 28558958
  16. the present study identified a positive correlation between EpCAM and COX-2 expression in breast cancer cell lines and tissue specimens. EpCAM and COX-2 were associated with the prognosis of breast cancer patients. PMID: 28393249
  17. CD133+ cells were genetically heterogeneous among patients without any defined profile compared to CD133-/EpCAM+ cells. PMID: 28347289
  18. Combining the targets E-cadherin, epithelial membrane antigen (EMA), human epidermal growth receptor type 2 (Her2/neu), carcinoembryonic antigen (CEA) resulted in nearly 100% detection of ductal ovarian metastases, whereas the combination of EMA, Her2/neu and epithelial cell adhesion molecule (EpCAM) was most suitable to detect lobular ovarian metastases. PMID: 28327103
  19. Whole-genome sequencing identified the homozygous intronic variant EPCAM c.556-14A>G, considered explanatory for the patient's intractable diarrhea and providing a diagnosis of congenital tufting enteropathy. PMID: 28701297
  20. Low EPCAM expression is associated with colorectal carcinoma. PMID: 26528695
  21. Our study provided clinical evidence for EpCAM intracellular domain as a predictor of cancer development in patients with oral dysplasia and recurrence in oral squamous cell carcinoma patients PMID: 27421772
  22. Elevated epithelial cell adhesion molecule EpCAM (mRNA+) CTC and Treg/CD4(+) levels were associated with early recurrence of hepatocellular carcinoma (HCC), indicative of poor clinical outcome. PMID: 27439521
  23. Observations provide important insights into the regulation of EpCAM expression during EMT, demonstrate an unexpected role for EpCAM in the regulation of ERK and define a novel double-negative feedback loop between EpCAM and ERK that contributes to the regulation of EMT. PMID: 28192403
  24. This study shows the potential of an EpCAM specific NIR-fluorescent agent in combination with a clinically validated intraoperative imaging system to visualize various tumours during surgery. PMID: 27842504
  25. The studies identified the characteristics and function of EpCAM glycosylation sites on breast cancer cell adhesion. PMID: 28315854
  26. These results identify EpCAM as a substrate of matriptase and link HAI-2, matriptase, EpCAM, and claudin-7 in a functionally important pathway that causes disease when it is dysregulated. PMID: 28094766
  27. The EpCAM aptamer conjugated NCS showed specificity to EpCAM-positive cells. PMID: 28668853
  28. Pseudomyxoma peritonei ubiquitously express CEA and EpCAM. PMID: 27038681
  29. relationship between EpCAM-regulated transcription and altered biophysical properties of cells that promoteepithelial-mesenchymal transition (EMT) in advanced endometrial cancer. PMID: 27569206
  30. used a next generation sequencing (NGS) approach. NY-SAR-35 expression induced growth, proliferation, metastasis, and stemness genes, as indicated by the up-regulations of CXCR4, EpCAM, CD133, and CD44, at the mRNA and protein levels PMID: 28126340
  31. These results indicate that adipocyte-secreted factors might regulate cancer stem cell behavior through several signaling molecules including c-Met, STAT3 and ERK1/2 and inhibition of these signaling pathways offer novel strategies in targeting the effect of adipose-derived cytokines in cancer. PMID: 27131739
  32. The meta-analysis demonstrated that the expression of EpCAM in the gastric cancer group was greater than that in the control group. Moreover, EpCAM overexpression was associated with larger tumour size, lymphnode metastasis and worse prognosis in gastric cancer. [review] PMID: 28403178
  33. expression of EpCAM(MT) is associated with a more aggressive phenotype and predicts poor survival in patients with colorectal cancer. PMID: 26996277
  34. Higher levels of epithelial cell adhesion molecule (EpCAM) in breast cancer may be associated with poor response to Neoadjuvant chemotherapy (NAC) via a potential chemoresistant effect. PMID: 27041736
  35. By monitoring the change of fluorescence signal, the target EpCAM protein could be detected sensitively and selectively with a linear detection range from 3nM to 54nM and limit of detection (LOD) around 450pM. In addition, this nanobiosensor has been successfully used for EpCAM-expressed breast cancer MCF-7 cell detection PMID: 27614683
  36. EpCAM, CD44 and CD133 expression could be candidate markers for Barrett esophagus disease progression PMID: 28216140
  37. These findings are important for a better understanding of epithelial cell adhesion molecule apoptosis regulation and suggest epithelial cell adhesion molecule as a potential target for the treatment of breast cancer. PMID: 28349835
  38. that epithelial cell adhesion molecule showed different expression pattern among salivary gland neoplasms and in different grades of mucoepidermoid carcinomas PMID: 27649957
  39. we concluded that the peptide could be a better supplement to the EpCAM antibody for capturing Circulating tumor cells (CTCs) in microfluidic system with broader spectrum PMID: 27818051
  40. This study presented a molecular characterization of congenital tufting enteropathy Italian patients, and identified three mutations in the EpCAM gene PMID: 26684320
  41. EpCAM serves as a potential biomarker of prognostic significance that could be used to identify oral squamous cell carcinoma patients at high risk and to predict patient survival PMID: 26401964
  42. Findings show that the EGF-like domain of EpCAM is cleaved off in cancer cells which have undergone epithelial-mesenchymal transition. PMID: 26775583
  43. Based on these results, it can be concluded that EpCAM is suitable for use as an EC biomarker, therapeutic target, and effective parameter for tumor transfer and prognosis evaluation by aptamer SYL3C staining PMID: 26687301
  44. CHD4 was abundantly expressed in EpCAM(+) hepatocellular carcinoma with expression of hepatic stem cell markers and poor prognosis in two independent cohorts. PMID: 26095183
  45. Flow cytometry assay showed doxorubicin exposure decreased EpCAM positive cell quantities in three HCC cell lines. EpCAM siRNA knock-down attenuated cell mortality after doxorubicin exposure PMID: 26984381
  46. EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except those low claudin expression. PMID: 26556851
  47. Increased Expression of EPCAM mRNA is associated with Recurrence After Curative Resection of Hepatocellular Carcinoma. PMID: 25791790
  48. We revealed a new molecular mechanism of MTA1-mediated invasion and metastasis in lung cancer through downstream target EpCAM, and interfering with EpCAM function may be a novel therapeutic strategy for treatment of MTA1-overexpressing lung carcinoma PMID: 26698569
  49. knockdown of EpCAM can inhibition breast cancer cell growth and metastasis via inhibition of the Ras/Raf/ERK signaling pathway and MMP-9 PMID: 26356670
  50. Results indicate that the anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibodie can potentially be used for cancer-targeted therapy. PMID: 26317650
  51. Data suggest soluble sEpCAM protein in malignant ascites as a potential predictive marker in cancer patients treated with catumaxomab. PMID: 26296970
  52. GbR201K-alphaEpCAM(scFv) is a promising novel targeted therapeutic for the treatment of triple negative breast cancer. PMID: 26806809
  53. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation. PMID: 25893293
  54. In this study, the authors developed a nanoparticle-mediated platform based on microfluidics to analyze the differential expressions of epithelial cell adhesion molecule (EpCAM) on CTCs in an animal model PMID: 25981337
  55. TROP-1/Ep-CAM and CD24 may play key roles in the progression of ovarian cancer through promoting migration, proliferation, inhibiting cell apoptosis and adhesion, and disturbing cell cycle. PMID: 26191160
  56. EpCAM can be used as a diagnostic biomarker for clinical detection of colorectal cancer. PMID: 26214441
  57. A major role of CD24 and EpCAM for the preservation of self-renewal capacity in MCF-7 cells. PMID: 25892097
  58. Results show that EpCAM overexpression in colorectal cancer cells is strongly associated with tumor progression, and may be regulated by epigenetic mechanisms. PMID: 25652097
  59. FACS analysis of transfected Hek293 cells overexpressing EpCAM 115Met/Thr showed binding of HO-3 to both proteins. PMID: 26115884
  60. Expression levels of EpCAM & beta-catenin were higher in cancer tissues compared with other tissues from the same patient. Their expression in colon cancers were correlated. Inverse correlation between their expression and patient prognosis was found PMID: 25966221
  61. EpCAM structure reveals that the extracellular part of EpCAM is folded in a compact shape and is not extending from the cell surface in a linear way. PMID: 25163760
  62. CTCs are detectable by EpCAM enrichment in metastatic hepatocellular carcinoma , without confounding false positive background from non-malignant liver diseases PMID: 25884197
  63. Data shows elevated levels of sEpCAM in a subgroup of cytology+ and in a small group of cytology- patients prompting the need for its level evaluation prior applying anti-EpCAM antibody-based cancer therapies since sEpCAM neutralizes catumaxomab activity. PMID: 25947366
  64. EpCAM regulated miR-181c and miR-130b may play significant roles in retinoblastoma progression. PMID: 25502397
  65. HEPCAM does not have a direct role as an adhesion molecule in carcinoma PMID: 26292218
  66. Knockdown of EpCAM promotes apoptosis, inhibits cell proliferation and causes cell-cycle arrest. PMID: 25019346
  67. YY1AP1 may serve as a key molecular target for EpCAM(+) AFP(+) HCC subtype PMID: 25597408
  68. microenvironment stimuli eliciting epithelial-to-mesenchymal transition are able to increase the dissemination potential of lung cancer cells through the generation of the CD133(+)/CXCR4(+)/EpCAM(-) subset. PMID: 26141860
  69. analysis of EpCAM expression and targeting reveals EpCAM-restricted proapoptotic activity toward rapidly proliferating carcinoma cells PMID: 24980949
  70. This study investigated the theranostic capabilities of nutlin-3a loaded poly (lactide-co-glycolide) nanoparticles functionalized with a targeting ligand (EpCAM aptamer) and an imaging agent (quantum dots) for cancer therapy and bioimaging. PMID: 25240596
  71. The results provide an important in vivo validation of hEpCAM signaling properties in normal epithelia and offer unique opportunities to further explore the function of this glycoprotein in select pancreatic cell lineages to elicit islet cell expansion. PMID: 26216137
  72. The identification of an EPCAM founder mutation has useful implications for the molecular diagnosis of LS in Spain. PMID: 23530899
  73. Serum EPCAM concentrations have no diagnostic, predictive, and prognostic roles in lung cancer patients. PMID: 25060911
  74. The expression of EpCAM was high on all carcinomas. PMID: 26124342
  75. This study reveals that both EpCAM and Trop2 overexpression in pituitary adenomas correlate significantly with invasiveness and proliferation. PMID: 25550831
  76. The elevated expression of EpCAM and/or CD133 is closely related to the carcinogenesis, progression, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma. PMID: 26176038
  77. EGF up-regulates EpCAM expression by activating ERK1/2 signaling in an ovraian cancer cell line, SKOV3. Additionally, EpCAM overexpression suppresses not only basal but also EGF-stimulated cell migration. PMID: 25576358
  78. Results show that high expression of nuclear Epithelial-intracellular domain of EpCAM was more frequent in breast cancers compared to normal tissues and correlated with poor prognosis. PMID: 25265904
  79. These findings provide, for the first time, mechanistic insights into how BAP31 regulates human embryonic stem cell stemness and survival via control of EpCAM expression. PMID: 24898727
  80. EpCAM loss may be a useful marker for determining microinvasion in hepatocellular carcinomas PMID: 25152593
  81. Both urinary EGFR and EpCAM are predictive of bladder cancer-specific survival. PMID: 25719831
  82. compared membranous ectodomain (EpEX) and intracellular domain (EpICD) EpCAM expression and prognosis in pancreatic adenocarcinoma PMID: 24117877
  83. The EpCAM expression pattern and its characteristic expression in resected hepatocellular carcinoma, was examined. PMID: 24696843
  84. On immunostaining, all cases of childhood hepatocellular carcinoma were positive for EpCAM; expression was diffuse (>50% of cancer cells) in 11 cases, and particularly strong in six children, all aged <3 years. PMID: 24138022
  85. study implicates the potential value of EpCAM as a molecular marker for breast cancer PMID: 25205054
  86. Data indicate that anti-EpCAM fusion toxin for tumor targeting by click PEGylation suggest new perspectives for effective cancer-related therapy. PMID: 24184633
  87. The overexpression of EpCAM in the stroma of intrahepatic cholangiocarcinoma is an independent risk factor for overall and disease-free survival; the overexpression of EpCAM in nontumor fibrous liver tissue is closely correlated with a worst disease-free survival PMID: 24909871
  88. These results indicate that the spatial localization of an intracellular domain of epithelial cell adhesion molecule and its mutual interaction with beta-catenin may be important in extrahepatic cholangiocarcinoma progression and invasion. PMID: 24888903
  89. High EPCAM mRNA expression levels are associated with recurrence of hepatocellular carcinoma. PMID: 24566861
  90. EpCAM overexpression was associated with esophageal squamous cell carcinoma. PMID: 24566863
  91. This study suggests the possibility that EpCAM, together with CD44v6 and claudin-7 as well as ALDH1, may be involved in the development of the aggressive phenotype of anaplastic thyroid carcinoma. PMID: 24727741
  92. SNP rs1126497 in the EPCAM gene may serve as an independent prognosis biomarker for unresectable hepatocellular carcinoma patient with portal vein tumor thrombus. PMID: 24718422
  93. Data indicate neither serum vascular cell adhesion molecule-1 (VCAM-1) levels nor serum epithelial cell adhesion molecule (EpCAM) levels were identified to have a prognostic role on either progression-free survival (PFS) and overall survival (OS). PMID: 24891186
  94. EpCAM expression is not steady throughout tumor progression but rather adapts to the requirements at the various stages of disease, as EpCAM directly influences proliferation, migration and invasion. PMID: 24141784
  95. EpCAM can be detected in the serum in patients with PDAC though the sensitivity for detecting PDAC is low and a correlation with clinical parameters was not found. PMID: 25202052
  96. The first step of EpCAM signalling takes place in prostate cancer cells. PMID: 24992580
  97. Ovarian tumor cell lines with methylated EpCAM promoter showed a reduction of EpCAM expression and a significantly reduced cell proliferation. PMID: 24489952
  98. The overexpression of EpCAM has correlation with the genesis of prostate cancer, especially androgen-dependent prostate cancer. PMID: 24705864
  99. these data identified combined expression levels of Aldh1, Survivin, and EpCAM as strong independent prognostic factors, with high hazard ratios, for survival and tumour recurrence in colorectal cancer patients, and therefore reflect tumour aggressiveness. PMID: 24786601
  100. In the titel. PMID: 23918549

Show More

Hide All

Involvement in disease Diarrhea 5, with tufting enteropathy, congenital (DIAR5); Hereditary non-polyposis colorectal cancer 8 (HNPCC8)
Subcellular Location Lateral cell membrane, Single-pass type I membrane protein, Cell junction, tight junction
Protein Families EPCAM family
Tissue Specificity Highly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal
Database Links

HGNC: 11529

OMIM: 185535

KEGG: hsa:4072

STRING: 9606.ENSP00000263735

UniGene: Hs.542050

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1